NewsResearch
FDA Approval: Lutetium-177 vipivotide tetraxetan (Pluvicto) for Prostate cancer
FDA approved Lutetium-177 vipivotide tetraxetan (Pluvicto), a radioligand therapy, for certain people with prostate cancer. What was approved, the evidence, and what it does and doesn't mean.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
Radiation delivered by the bloodstream
Most radiation therapy is aimed from outside the body at a target the team can see. Lutetium Lu 177 vipivotide tetraxetan, sold as Pluvicto, works differently. Its FDA label calls it a radioligand therapeutic agent, and its Initial U.S. Approval date is 2022.
A radioligand has two parts joined together. One part is a molecule that seeks out a specific protein. The other is a radioactive atom, here lutetium-177. Injected into a vein, the seeking molecule finds its target and carries the radiation to it, wherever in the body that target sits.
The target is prostate-specific membrane antigen, or PSMA, a protein carried in large amounts on many prostate cancer cells.
Selection by scan, not by guess
The label is explicit about who can receive it. Patients are selected using Locametz, whose active ingredient is gallium Ga 68 gozetotide, or another approved PSMA positron emission tomography product, based on PSMA expression in the tumor.
So a PET scan comes first, using a tracer that binds the same target. If the tumor lights up, the therapy has something to bind to. If it does not, there is no delivery route.
The label covers adults with PSMA-positive metastatic castration-resistant prostate cancer. They must have had an androgen receptor pathway inhibitor. And they must be fit to delay taxane chemotherapy, or have already had it. Castration-resistant means the cancer is growing despite treatment that keeps testosterone very low.
The 2025 expansion, and its honest result
On March 28, 2025, the FDA expanded the indication to include people appropriate to delay taxane chemotherapy, rather than only those who had already received it.
The evidence was PSMAfore, a randomized, open-label trial at many centers. It enrolled 468 patients whose disease had progressed on one androgen receptor pathway inhibitor. They were randomized one to one. One arm got the radioligand, at 7.4 GBq every 6 weeks for 6 doses. The other arm switched to a different androgen receptor pathway inhibitor. Patients who progressed in that arm could cross over.
Median radiographic progression-free survival was 9.3 months with the radioligand and 5.6 months in the comparison arm, with a hazard ratio of 0.41.
Overall survival was the additional outcome, and here the result was different. Median overall survival was 24.5 months versus 23.1 months, with a hazard ratio of 0.91, and the difference was not statistically significant.
Sixty percent of patients in the comparison arm, 141 people, crossed over to the radioligand after progression. Crossover makes an overall survival difference harder to detect, because people in both arms end up receiving the drug.
That pairing is the kind of thing a headline flattens. Both numbers are real. They answer different questions.
The safety issues that come with radiation
The label carries no contraindications, but it does carry four warnings.
Radiation exposure. The label tells teams to keep exposure low during and after treatment. Patients are told to drink more fluid and to void often. That cuts the radiation dose to the bladder.
Myelosuppression. Blood counts fall. Counts are checked, and the drug may be held, reduced, or stopped.
Renal toxicity. Patients are told to stay well hydrated and urinate often. Kidney tests are done, and the dose is changed as needed.
Embryo-fetal toxicity. The drug can cause fetal harm.
The dose is 7.4 GBq, or 200 millicuries, into a vein every 6 weeks for 6 doses.
When to get checked
NCI notes that prostate cancer is most common in older men, and that about one in eight men in the United States will be diagnosed with it.
Check with a doctor for:
- Trouble starting the flow of urine.
- Frequent urination, especially at night.
- Trouble emptying the bladder completely.
- A weak or interrupted, stop-and-go, flow of urine.
NCI lists a second set that can appear when prostate cancer is found at an advanced stage: pain in the back, hips, or pelvis that does not go away, and shortness of breath, severe tiredness, fast heartbeat, dizziness, or pale skin caused by anemia.
One caution sits alongside that list. As men age, the prostate often enlarges and blocks the urethra or bladder. That is benign prostatic hyperplasia, or BPH. It is not cancer. Its symptoms can look the same. Only testing tells them apart.
PSA, Gleason, and Grade Group
The PSA test measures prostate-specific antigen, a substance made by the prostate that can be raised in men with prostate cancer. A digital rectal exam checks the gland by touch. A needle biopsy confirms or rules out cancer.
Staging uses PSA level, Grade Group, and the extent of disease. Grade Group comes from the Gleason score, a measure of how abnormal the cells look. Grade Group 5, the highest, matches a Gleason score of 9 or 10.
Stage I means cancer confined to the prostate, with a PSA below 10 and Grade Group 1. Stage II is more advanced but still confined to the prostate. Later stages describe spread beyond it.
Where this sits in treatment
For localized disease, options include monitoring, surgery, and radiation. For cancer that has spread, treatment starts by lowering testosterone, then adds androgen receptor pathway inhibitors, then taxane chemotherapy, and then agents like this radioligand.
Our page on prostate cancer covers the earlier stages, and biomarker testing covers the tests that decide eligibility for treatments like this one.
Numbers dominated by early disease
These SEER figures cover all US prostate cancer, most of which is found early. They describe a population, not a person, and they do not describe the advanced group this drug treats.
Five-year relative survival is 98.2 percent for cases from 2016 to 2022. By stage it is 100.0 percent while confined to the prostate, 100.0 percent when it involves nearby lymph nodes, and 40.1 percent once it has spread to distant sites. About 69 percent are found while still confined, and 9 percent are distant at diagnosis. The American Cancer Society projects 333,830 new cases and 36,320 deaths for 2026, and NCI puts median age at diagnosis at 68.
The gap between 100.0 and 40.1 percent is where this drug is used.
What this approval cannot tell you
The 2025 change moved the drug earlier in the sequence, ahead of taxane chemotherapy for some men. It did not show that people live longer.
Access is a real constraint too. This is a radioactive therapy given at licensed centers, after a PSMA PET scan. Whether it fits one person depends on the scan result, prior treatments, blood counts, and kidney function.
Sources
- FDA, FDA expands Pluvicto's metastatic castration-resistant prostate cancer indication — https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication
- DailyMed, PLUVICTO label, Initial U.S. Approval 2022 — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14908037-2892-4d98-a053-253ce35afb1a
- NCI, Lutetium Lu 177 Vipivotide Tetraxetan — https://www.cancer.gov/about-cancer/treatment/drugs/lutetium-lu-177-vipivotide-tetraxetan
- NCI PDQ, Prostate Cancer Treatment (Patient Version) — https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq
- SEER Cancer Stat Facts, Prostate Cancer — https://seer.cancer.gov/statfacts/html/prost.html
How this article was prepared
An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.
The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.
See an error, old source, or unclear wording? Tell us.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Prostate cancer. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.